Literature DB >> 10672328

Practical measures to simplify the Braak tangle staging method for routine pathological screening.

A J Harding1, J J Kril, G M Halliday.   

Abstract

The examination of neurofibrillary tangles is now recommended for the diagnosis of Alzheimer's disease as their location and density can distinguish early, intermediate and late disease stages. While the Braak tangle staging protocol can identify these stages, it uses an uncommon silver stain and hippocampal sample. The present study evaluates the Braak protocol using commonly used methods and cases fulfilling either CERAD criteria for Alzheimer's disease, criteria for dementia with Lewy bodies or without neurological disease. Temporal and occipital cortices from 72 cases were stained using tau immunohistochemistry and the Gallyas and modified Bielschowsky silver stains. The modified Bielschowsky silver stain was equivalent to the Gallyas silver stain for tangle staging. Semiquantitative evaluation of neurofibrillary tangles in the hippocampus and the inferior temporal cortex provided equivalent information to that obtained using the original Braak tangle staging protocol (kappa statistic of 0.97). Comparison of this modification with the CERAD criteria provided moderate agreement (0.51) between diagnostic categories when cases with dementia with Lewy bodies were included, but substantially increased agreement (0.74) when they were excluded. This simplification of the Braak tangle staging protocol is easy to apply, can be readily incorporated into existing CERAD procedures, and helps to distinguish cases with neurofibrillary tangles from those with Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10672328     DOI: 10.1007/pl00007425

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  5 in total

1.  Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS.

Authors:  F Tassone; C M Greco; M R Hunsaker; A L Seritan; R F Berman; L W Gane; S Jacquemont; K Basuta; L-W Jin; P J Hagerman; R J Hagerman
Journal:  Genes Brain Behav       Date:  2012-04-06       Impact factor: 3.449

2.  Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss.

Authors:  J J Kril; S Patel; A J Harding; G M Halliday
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

3.  Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients.

Authors:  Dietrich E Lorke; Gang Lu; Eric Cho; David T Yew
Journal:  BMC Neurosci       Date:  2006-04-27       Impact factor: 3.288

4.  Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis.

Authors:  Timothy A Couttas; Nupur Kain; Benjamin Daniels; Xin Ying Lim; Claire Shepherd; Jillian Kril; Russell Pickford; Hongyun Li; Brett Garner; Anthony S Don
Journal:  Acta Neuropathol Commun       Date:  2014-01-23       Impact factor: 7.801

5.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.